Abstract We studied the regulation of the individual natriuretic peptide receptor subtypes by 12-O-tetradecanoylphorbol 13-acetate (TPA) and forskolin in cultured bovine aortic endothelial and smooth muscle cells. In cultured endothelial cells, 10"' mol/L TPA caused a reduction in atrial natriuretic peptide (ANP) receptor binding activity that was seen as early as 2 hours after the treatment and reached a maximum (88±3% of control) after 24 hours, whereas the inhibition of ANP-stimulated cyclic GMP (cGMP) accumulation peaked at 2 hours (62±13% of control) and returned to control levels after 12 hours. After 24 hours of forskolin (10~4 mol/L) treatment, ANP binding activity fell to 47±6%, and cGMP accumulation was 52±11% of control. Northern blot analysis revealed that 10~8 mol/L TPA suppressed natriuretic peptide C receptor transcript levels, and forskolin increased levels modestly after 24 hours of treatment. Natriuretic peptide A receptor transcript levels remained unchanged by either treatment. In cultured smooth muscle cells, 10" 8 mol/L TPA suppressed ANP binding activity and ANP-stimulated cGMP T he natriuretic peptides play an important role in the regulation of blood pressure and body fluid homeostasis. 1 -2 Atrial natriuretic peptide (ANP), the first of the peptides to be described, is produced predominantly in the atria of the heart but can also be found in cardiac ventricle and other extracardiac locations.
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Abstract We studied the regulation of the individual natriuretic peptide receptor subtypes by 12-O-tetradecanoylphorbol 13-acetate (TPA) and forskolin in cultured bovine aortic endothelial and smooth muscle cells. In cultured endothelial cells, 10"' mol/L TPA caused a reduction in atrial natriuretic peptide (ANP) receptor binding activity that was seen as early as 2 hours after the treatment and reached a maximum (88±3% of control) after 24 hours, whereas the inhibition of ANP-stimulated cyclic GMP (cGMP) accumulation peaked at 2 hours (62±13% of control) and returned to control levels after 12 hours. After 24 hours of forskolin (10~4 mol/L) treatment, ANP binding activity fell to 47±6%, and cGMP accumulation was 52±11% of control. Northern blot analysis revealed that 10~8 mol/L TPA suppressed natriuretic peptide C receptor transcript levels, and forskolin increased levels modestly after 24 hours of treatment. Natriuretic peptide A receptor transcript levels remained unchanged by either treatment. In cultured smooth muscle cells, 10" 8 mol/L TPA suppressed ANP binding activity and ANP-stimulated cGMP T he natriuretic peptides play an important role in the regulation of blood pressure and body fluid homeostasis. 1 -2 Atrial natriuretic peptide (ANP), the first of the peptides to be described, is produced predominantly in the atria of the heart but can also be found in cardiac ventricle and other extracardiac locations. 3 - 4 Brain natriuretic peptide (BNP) is also produced in the heart, albeit at lower levels than ANP. 5 - 6 In most systems in which it has been studied, BNP behaves like ANP with equivalent or slightly weaker potency. C-type natriuretic peptide (CNP) is produced predominantly in the brain 7 but is also found in a number of peripheral locations including the vascular endothelium. 8 CNP has some important structural differences relative to the other natriuretic peptides in that it lacks the carboxy-terminal extension (beyond the cystine bridge), which is important for the biological activity of the other natriuretic peptides. 9 CNP has been suggested to show preferential activity in the vasculature, whereas ANP and BNP act predominantly in the kidney. 10 These peptide ligands bind to one or more of the membrane-associated natriuretic peptide receptors (NPRs) present on target cells. Three NPRs have been described to date. The NPR-A and NPR-B subtypes represent ligand-regulated forms of the particulate guanylate cyclase.
11 NPR-A is believed to mediate most if not all of the known biological activities of ANP, 1 -2 and NPR-B is preferentially activated by CNP.
12 NPR-C has been shown to function in a clearance mode with responsibility for controlling concentrations of the various natriuretic peptides in the periphery. 13 Several recent studies, however, suggest an additional signaling role for this receptor that may prove important in promoting the full biological activity of the natriuretic peptides 14 at the level of the target cell.
NPRs are regulated by a variety of hormones and vasoactive peptides. Several investigators have reported heterologous downregulation of receptor levels after treatment with natriuretic peptide ligand, 1516 although this remains controversial. 17 Treatment of rat vascular smooth muscle cells with glucocorticoids resulted in a significant reduction in ANP-sensitive cyclic GMP (cGMP) production in these cells. 18 Similar treatment of pulmonary artery endothelial cells led to an increase rather than a decrease in receptor binding activity, 19 indicating a lack of uniformity in the response to these steroids. Receptor levels have also been shown to decrease on the surface of target cells after treatment with endothelin, 20 27 The latter finding is of interest in that PKC activation has been invoked as a potential effector mechanism with each of the peptide regulators listed above. However, little is known regarding the mechanism or mechanisms underlying the PKC-dependent effect and what interplay, if any, it has with other protein kinase activators. In the present study, we have examined the regulation of the individual receptor subtypes by TPA and forskolin, an activator of protein kinase A (PKA) activity, in both bovine aortic endothelial (BAE) and smooth muscle (BASM) cells. Our findings suggest that the regulatory effects of the kinase activators are specific for the individual receptor subtypes as well as the cell types that express them.
Methods Materials
ANP (rANF, 28 amino acids) and CNP (porcine, CNP 1J2 ) were purchased from Peninsula Laboratories, Inc. 3-Isobutyl-1-methylxanthine (IBMX), TPA, and forskolin were purchased from Sigma Chemical Co. Reagents for cGMP radioimmunoassay and p^a -d C T P were purchased from New England Nuclear Corp. Enriched calf serum was purchased from Gemini Bioproducts, Inc. Other chemicals and cell culture reagents were purchased from standard commercial suppliers. The bovine ANP-C receptor cDNA and the rat ANP-A and ANP-B receptor cDNAs were generously provided by Drs Gordon Porter and David Garbers, respectively.
Cell Culture
BAE cells (second passage) were provided by Dr Jeffry Lansman (University of California at San Francisco). Typically, passages 4 to 9 were used for the work reported here. BASM cells were obtained at passage 3 and studied between passages 4 and 10. Cells were grown to confluence in Dulbecco's modified Eagle medium (DMEM) H-21 supplemented with 10% enriched calf serum, 2 mmol/L glutamine, and penicillin/streptomycin (100 IU/mL and 100 it%!mL, respectively) at 37°C in a 95% air, 5% CO 2 humidified atmosphere. Medium was changed every 2 to 3 days.
For studies involving receptor measurement, cells were plated in 24-well plates at a density of 5 x 10 4 cells per well and grown to confluence in serum-containing medium. The cells were then transferred to serum-free medium containing 10% serum substitute, 28 2 mmol/L glutamine, 100 IU/mL penicillin, 100 jtg/mL streptomycin, 5 ^tg/mL insulin, 5 /xg/mL transferrin, and 1 /ig/mL vitamin B 12 for 24 hours. At that point fresh serum-free medium was added, with or without TPA and/or forskolin, as described in the individual experimental protocols.
Measurement of ANP Binding
ANP was labeled with 125 I-Na using the chloramine T method and purified as described previously. 3 The specific activity of the 125 I-ANP was 300 to 700 /iCi/Mg (919 to 2142 Ci/mmol). The binding properties of this material, after intermittent repurification, remained constant for at least 4 weeks. Binding assays were performed in 24-well plates on confluent cell monolayers, as described by Lehman et al, 29 with slight modification. Briefly, cells were washed twice with 1 mL phosphate-buffered saline (PBS) and incubated with 200 /AL DMEM containing 10 mmol/L HEPES, 0.2% bovine serum albumin (BSA), and 0.5 to 0.8 x 10"' mol/L 123 I-ANP. After 25 minutes of incubation at 37°C, the cells were washed four times with cold PBS containing 0.2% BSA and solubilized with 1 mL of IN NaOH, and 900-^.L aliquots were assayed for the total bound radioactivity (total binding). Nonspecific binding was determined in parallel untreated or treated cells receiving identical amounts of 125 I-ANP as well as 10" 7 mol/L unlabeled ANP. Specific binding was computed as the difference between total and nonspecific binding and routinely represented 85% to 90% of total binding. For Scatchard analysis, 12! I-ANP was added at increasing concentrations in the presence or absence of 10~7 mol/L unlabeled ANP. The dissociation constant (Kj) and maximum binding (B mx ) were calculated using a computer program described previously. 30 To determine the binding on the cell surface and in the intracellular compartment separately, cells were incubated with 1.5x10"' mol/L 12! I-ANP in the buffer system described above for 25 minutes at 37°C or 4 hours at 4°C. Cells were washed four times with cold PBS containing 0.2% BSA then incubated at 4°C for two 15-minute intervals in 0.2 mol/L acetic acid plus 0.5 mol/L NaCl to remove surface-bound ligand. 31 Binding on the cell surface was determined by measurement of the radioactivity removed by the acid wash. The cells were then solubilized with 1 mL of IN NaOH, and 900 -fiL aliquots were assayed for binding in the intracellular compartment. Specific binding was determined by inclusion of 1.5xlO~7 mol/L unlabeled ANP as described above.
Measurement of Cyclic Nucleotide Levels
Cells were grown to confluence in 24-well plates. After pretreatment with agonists, the cells were washed twice with warm PBS and preincubated at 37°C for 10 minutes with 450 iiL DMEM containing 10 mmol/L HEPES and 0.5 mmol/L IBMX. ANP,.^ or CNP,.^ was then added to cultures in a 5-/iL volume to achieve the desired final concentration, and the incubation continued for an additional 10 minutes. Medium was aspirated and the reaction terminated by addition of 0.5 mL cold 10% trichloroacetic acid. After a 30-minute incubation at 4°C, the cellular extracts were collected and centrifuged at 12 000 rpm for 3 minutes. The supernatant was then extracted four times with water-saturated ether. cGMP was measured directly by radioimmunoassay. Both samples and cGMP standards were acetylated before assay. In independent experiments the forskolin effect on cellular cyclic AMP (cAMP) levels was assessed. After either 10 minutes or 24 hours of treatment with 10" 4 mol/L forskolin under serumfree conditions, medium was aspirated and replaced with 0.5 mL cold 10% trichloroacetic acid. Samples were processed as described above, and cAMP was measured by radioimmunoassay using a commercially available antiserum (Sigma).
RNA Isolation and Northern Blot Analysis
Cells were treated for 24 hours with the agonist of interest, and total RNA was extracted according to the method of Chirgwin et al. 32 Total RNA (30 fig) was size fractionated on a 1% agarose gel containing 2.2 mol/L formaldehyde, transferred by capillary action to a nitrocellulose membrane (GeneScreen Plus, New England Nuclear) in 10 x SSC (1.5 mol/L sodium chloride and 0.15 mol/L sodium citrate) for 8 to 16 hours, and fixed to the membrane by UV irradiation (DNA transfer lamp, Fotodyne Inc). The membrane was then baked at 80°C for 1 hour. The full-length (2.1-kb) bovine NPR-C cDNA, isolated as a MndIII-£coRI fragment, 33 a 1.2-kb EcoRI fragment from the 5' end of the rat NPR-A cDNA, 34 or a 1.3-kb £coRI-£amHI fragment from the rat NPR-B cDNA 35 was labeled with [^Jo-dCTP using the random primer technique. 36 Hybridizations were performed overnight at 42°C using conventional techniques. 36 Blots were also probed with a 1.3-kb Pst I fragment from the human GAPDH cDNA 37 to control for loading and transfer of total RNA in individual samples.
Statistical Analysis
Data were subjected to one-way ANOVA and the NewmanKeuls test to test for significance.
Results
To determine the dose-response relation of the individual agonists to ANP binding activity, we treated BAE cells with increasing concentrations of TPA or forskolin in serum-free medium for 24 hours and then subjected them to the binding assay (Fig 1) . TPA (10" 8 mol/L), an activator of PKC, produced an 88±3% inhibition of ANP binding activity compared with untreated cells. This reduction was not seen using the same concentration of 4a-TPA, a biologically inactive TPA analogue (data not shown). Forskolin, an activator of adenylate cyclase that leads to an increase in PKA activity, produced a similar, albeit weaker, reduction in binding activity. Concentrations of 10~5 and 10~4 mol/L forskolin caused a 32±6% and 53±6% decrease in ANP binding, respectively.
To investigate the kinetics of the TPA-and forskolindependent inhibition and to determine which of the ANP receptor subtypes are regulated by these agonists, we cultured BAE cells with 10" 8 mol/L TPA or 10~4 mol/L forskolin for varying periods of time before measuring ANP binding and ANP-stimulated cGMP accumulation. Measurable I25 I-ANP binding activity describes primarily binding to the NPR-C in these cells where 85% or more of the total binding has been assigned to this receptor subtype. 29 As shown in Fig 2A , TPA caused a reduction in ANP binding activity (15 ± 3 % of control) as early as 2 hours into treatment and reached a maximum (88±3% of control) after 24 hours. Additional studies not presented here suggest that TPA-dependent inhibition of ANP binding activity persisted for up to 48 hours after exposure to the agonist. We next examined the effect of TPA on ANPstimulated cGMP production. The latter provides an indirect measure of NPR-A activity in endothelial cells because NPR-A is thought to be the predominant guanylyl cyclase-linked receptor subtype in this cell type. 38 Under basal conditions in the presence of 0.5 mmol/L IBMX, 10" 7 mol/L ANP generated 1.73±0.3 pmol cGMP per microgram DNA per 10 minutes. As shown in Fig 2B, 10" 8 mol/L TPA suppressed ANPstimulated cGMP production; however, in contrast to the effect on binding activity, the effect on cGMP production was maximal after 2 hours (62 ±13% of control) and recovered to control levels after 12 hours of treatment. In our hands, CNP-stimulated (10~7 mol/L) cGMP production, which is an indirect measure of NPR-B, is less than 2% of that seen after treatment with ANP (data not shown), supporting the contention of other researchers 38 that NPR-A is the dominant guanylate cyclase-linked receptor in these cells. Forskolin also reduced ANP binding activity (Fig 2A) and ANPstimulated cGMP production in BAE cells ( Fig 2B) ; however, by way of contrast to the TPA-mediated effects, the binding activity and ANP-stimulated cGMP accumulation were reduced in parallel by forskolin. After 2 hours of treatment with 10~4 mol/L forskolin, ANP binding activity was decreased to 83±3% of control, and ANP-stimulated cGMP was decreased to 81 ±7% of control; after 24 hours of treatment, ANP binding activity was 47 ±6% and cGMP accumulation was 52±11% of control. Forskolin at 10~4 mol/L produced approximately a doubling of cellular cAMP levels (control, 0.775±0.005 pmol per well; forskolin, 1.525±0.085 pmol per well; P<.0l) after a 10-minute treatment, and the response persisted for the remainder of the 24-hour experimental period. tential additrvity at the level of the guanylate cyclaselinked receptors, we measured ANP-stimulated cGMP production following a similar treatment protocol. In this case, we collected cells after 24 hours of exposure to 10" 4 mol/L forskoiin, adding 10"' or 10" 8 mol/L TPA for the last 2 hours of the incubation in an effort to maximize the responses to the individual agonists (see Fig 2) . As expected (Fig 4B) , both TPA and forskoiin independently fostered a reduction in cGMP produc- tion; however, when maximal concentrations of each were used, no additivity was seen, suggesting a potential convergence in their respective effector pathways.
The findings presented above imply that TPA and forrkolin suppress ANP binding activity primarily by reducing the number of available receptor sites. It has been reported that NPR-C, which accounts for 85% or more of the total NPRs in cultured BAE cells, 29 undergoes a substantial degree of endocytosis and recycling at 37°C. 31 With this taken into consideration, the possibility could not be excluded that TPA and/or forskolin might influence the rate of receptor endocytosis and/or recycling and thereby cause a reduction in binding activity by selectively depleting receptor in the intracellular compartment. To explore this possibility, we pretreated endothelial cells with 10" 8 mol/L TPA or 10"" mol/L forskolin for 24 hours. Binding assays were then performed at 37°C and 4 C C as described in "Methods." Total specific binding, binding on the cell surface, and binding in the intracellular compartment were determined separately. As expected, treatment with TPA and forskolin resulted in an 82% and 58% inhibition of total specific ANP binding activity, respectively, at 37°C ( Fig  5A) . Cell surface binding accounted for most of the total specific binding in the cultures, with a much smaller percentage represented by the binding in the intracellular compartment. Treatment with TPA and forskolin reduced surface and intracellular binding in parallel, arguing against selective depletion of an intracellular ligand pool as an explanation of the observed inhibition. A similar reduction in surface binding was observed when the experiment was carried out at 4°C (Fig 5B) . In this latter case virtually all cellular binding activity was confined to the surface compartment, presumably reflecting suspension of the temperature-dependent receptor internalization process.
On the other hand, the protracted kinetics of the inhibitory effect of ANP binding activity by TPA and forskolin suggest the possibility of an effect on new receptor synthesis. To address this issue, we pretreated BAE cells with varying concentrations of TPA, forskolin, or TPA plus forskolin for 24 hours and measured the steady-state levels of the mRNA transcripts for the individual NPRs (Fig 6) . Hybridization of 30 /ig total RNA with a radiolabeled cDNA probe for the bovine NPR-C revealed two bands migrating at 9 and 4 kb, respectively. Additional studies not presented here suggest that the 9-kb band represents the major specific NPR-C transcript. TPA caused a dose-dependent reduction in NPR-C mRNA. This effect was most apparent with the 9-kb transcript, in which 84% inhibition was observed at 10" 8 mol/L TPA (Fig 6A) . Forskolin increased NPR-C transcript levels by 58% at 10" 4 mol/L when used alone. The combination of forskolin and TPA appeared to be dominated by the inhibitory activity of the latter (lanes 7 and 8). Hybridization with a rat cDNA probe for NPR-A transcript revealed a single 4-kb band (Fig 6B) . Neither TPA nor forskolin, alone or in combination, had a significant effect on levels of this transcript in these cultured BAE cells. As shown in the same figure, levels of the GAPDH transcript were relatively unaffected by TPA and/or forskolin, arguing against variability in RNA loading or transfer among individual samples. Ethidium bromide staining of ribosomal RNA on the gels confirmed this impression (data not shown). The NPR-B transcript in BAE cells was not detectable using the methods employed here.
Next, we extended our analysis to the vascular smooth muscle cell. These cells lie in close apposition to vascular endothelial cells in vivo and are known to be subject to significant paracrine regulation by the latter. 39 Thus, differential sensitivity to the natriuretic peptides could have important implications in terms of the maintenance of vascular tone and integrity. Cultured BASM cells possess an abundance of ANP receptors, predominantly (>95%) of the NPR-C subtype. Like their endothelial counterparts, they harbor a minor population of guanylyl cyclase-linked receptors, although these are believed to be predominantly of the NPR-B rather than the NPR-A subtype. NPR-C, NPR-A, and NPR-B activity, respectively. As shown in Fig 7, 10" 8 mol/L TPA suppressed ANP binding activity (Fig 7A) and ANP-stimulated cGMP formation (Fig 7B) in a fashion similar to that seen in BAE cells, although both responses peaked earlier in BASM cells. TPA treatment also resulted in an inhibition of CNP-stimulated cGMP production ( Fig 7C) ; however, the kinetics of this response were quite different when compared with the inhibition of ANP-stimulated cGMP production. Maximal inhibition (59 ±7% of control) was detected after a 4-hour exposure to TPA, but although the response to ANP returned to control levels over the ensuing 20 hours, the response to CNP persisted for the duration of the experiment. Treatment with 10~* mol/L forskolin produced a time-dependent inhibition of ANP binding activity similar to that seen in BAE cells (Fig 7A) . In contrast to its effects in BAE cells, forskolin did not inhibit either ANP-stimulated or CNP-stimulated cGMP production in BASM cells (Fig  7B and 7C) .
The extended kinetics of the TPA-and forskolinmediated effects on ANP binding activity and the TPA-mediated suppression of CNP-stimulated cGMP production in BASM cells again raised the possibility that effects on receptor synthesis might be involved in these responses. To evaluate this possibility, we treated BASM cells with varying concentrations of TPA, forskolin, or TPA plus forskolin for 24 hours and examined steady-state levels of mRNA transcripts for the individual NPR subtypes by Northern blot analysis (Fig 8) . Interestingly, the RNA analyses revealed a much different regulatory profile in BASM versus BAE cells. First, in contrast to its inhibitory effect on NPR-C mRNA levels in BAE cells, TPA produced a dose-dependent stimulation of this transcript in BASM cells (Fig 8A, 114% increase at 10~8 mol/L TPA). This was observed despite the obvious reduction in ANP binding in the latter. Second, although forskolin evoked a modest increase in NPR-C transcript levels in BAE cells, it caused a dose-dependent reduction in these transcripts in BASM cells (Fig 8A, 71% decrease at 10" 4 mol/L forskolin). Once again, the combined effect of TPA and forskolin was dominated by the inhibitory agonist, in this case forskolin. As seen previously with the BAE cells, neither TPA nor forskolin, alone or in combination, had a significant effect on levels of NPR-A and NPR-B transcripts in the BASM cells (Fig 8B and 8Q .
Discussion
Our data, as summarized in the Table, suggest that the activated forms of PKC and PKA negatively regulate ANP receptor activity in cultured BAE and BASM cells; however, the characteristics of these inhibitions are quite distinct, suggesting important differences in the mechanisms underlying them. In endothelial cells TPA and forskolin caused an 88% and 53% inhibition of ANP binding activity, respectively. Since approximately 85% to 90% of the receptors on these cells represent NPR-C, the reduction in binding, by definition, predominantly involves this receptor subtype. Similarly, with the use of ANP-stimulated cGMP accumulation as an indirect marker of NPR-A activity, TPA was shown to effect a similar suppression of this receptor. Here, however, an important difference becomes apparent. Although the fall in binding activity persisted throughout the 24-hour time course of the experiment, implying progressive suppression of NPR-C, inhibition of NPR-A activity peaked at 2 hours and returned to control levels after 8 hours of exposure to the agonist. This likely reflects the well-recognized downregulation of PKC activity that occurs after prolonged exposure to the phorbol ester. 27 The time dependency of the TPA effect on NPR-A activity has practical importance in that sample timing will clearly determine whether one sees the inhibition or not. Assuming that both the reduction in binding and the inhibition of guanylate cyclase reflect enhanced PKC activity, it would suggest that the time constants for recovery from the inhibition, following reduction of PKC activity, are quite different for NPR-C and NPR-A and imply that independent mechanisms are involved in the suppression of the different receptor subtypes. The Northern blot data presented in Fig 6 may shed some light on this issue. TPA caused a dose-dependent reduction in NPR-C mRNA levels but had no effect on levels of the NPR-A transcript. Taken in the context of the binding data, this leads us to the obvious hypothesis that TPA, through activation of PKC activity, reduces NPR-C levels at least partially through an effect on receptor synthesis, whereas the suppression of NPR-A occurs through a posttranscriptional mechanism, possibly through modification of presynthesized receptor. A priori, one would predict that the kinetics of reversing the latter phenomenon would be faster than those controlling the return of receptor synthesis, which would be determined in part by the respective half-lives of the NPR-C transcript and protein. 40 It should be noted that our demonstration of a TPA-mediated reduction in NPR-C transcript levels does not preclude the coexistence of an independent and potentially equally important effect of the agonist at a posttranscriptional locus.
Activation of PKA by forskolin, on the other hand, resulted in a comparable time-dependent reduction of both NPR-C and NPR-A activity (Fig 2B) , reflecting the fact that PKA does not downregulate with prolonged exposure to the agonist. The fact that the reduction in binding activity was not accompanied by a reduction in NPR-C or NPR-A transcript levels (there was in fact a modest increase in the former) in these endothelial cells suggests that PKA acts at a level distal to mRNA accumulation, possibly at a translational or posttranslational locus.
Since the characteristics of their respective inhibitory effects appear similar, it is reasonable to ask whether PKC and PKA exert their effects through a similar or common mechanism. Although we cannot address this question definitively, the results of the experiments presented in Fig 4 would suggest that this may be the case. Whereas submaximal concentrations of TPA and forskolin were clearly additive in suppressing ANP binding to the surface of endothelial cells, the addition of forskolin to maximal concentrations of TPA produced no further effect, implying that these two kinase systems may use a final common pathway to control receptor activity in BAE cells. If so, this would support the notion that TPA possesses a second inhibitory activity that acts distal to NPR-C mRNA accumulation and at a locus that is under the shared regulatory control of the two kinase pathways.
When the experimental paradigm was extended to BASM cells, both TPA and forskolin were found to suppress 125 I-ANP binding activity. However, whereas TPA caused the same temporally abbreviated inhibition of ANP-stimulated guanylate cyclase activity seen in BAE cells, forskolin had no effect. In addition, CNPstimulated cGMP accumulation was also suppressed by TPA and unaffected by forskolin. In the case of TPA, the effect persisted throughout the 24-hour time course of the experiment, representing a significant departure from the effect on ANP-stimulated cyclase described above. These findings are important for a number of reasons. First, they imply the presence of NPR-A (ie, ANP-stimulated guanylate cyclase activity) in these BASM cells. Although other researchers have reported that the guanylyl cyclase-linked receptors in cultured vascular smooth muscle cells are predominantly of the NPR-B subtype, the predominant form found in vascular smooth muscle in vivo is NPR-A. 41 Our findings would suggest that the BASM cells used here possess an intermediate phenotype, perhaps reflecting the early passage number of the cells chosen for study, and express both NPR-A and NPR-B. Second, they point out an important distinction relative to BAE cells in that neither guanylate cyclase-linked receptor was suppressed by activation of PKA in BASM cells. Finally, they suggest that TPA differentially regulates NPR-A and NPR-B. If we assume that the reversal of the TPA-dependent suppression of NPR-A reflects downregulation of PKC, our data would imply that NPR-B, like NPR-C, has a delayed time course of recovery relative to NPR-A.
Another intriguing difference between the vascular endothelial and smooth muscle cells relates to the effects of the agonists on steady-state levels of NPR-C transcripts. Comparison of the results presented in Figs 6 and 8 shows that TPA reduced levels of the NPR-C mRNA in a dose-dependent fashion in BAE cells but increased levels of the transcript in BASM cells, a finding that, in view of the reduction in NPR-C binding activity in these latter cells, must be considered reactive or compensatory rather than causal. Thus, the nature of the mechanism underlying the inhibition of binding activity in vascular smooth muscle cells and whether it is shared to any extent by their endothelial counterparts remain undefined. Forskolin, on the other hand, had a modest stimulatory effect on NPR-C transcripts in BAE cells but suppressed these transcripts in BASM cells, implying that a reduction in available template for new receptor synthesis may be of mechanistic importance in the latter but not the former cell type.
Regulation of NPR-A and NPR-B, in view of the lack of agonist effects on their respective transcript levels, probably occurs at a translational or posttranslational locus. Duda and Sharma, 42 in exploring the negative regulation of ANP-dependent guanylate cyclase activity in rat adrenocortical carcinoma cells, showed that PKC phosphorylated the ANP-coupled 180-kD guanylate cyclase in vitro. This suggests that direct phosphorylation of the receptor may play a key role in the TPAmediated functional activity described here. On the other hand, Potter and Garbers 43 reported that dephosphorylation of NPR-A was associated with desensitization of cyclase activity in their transfected HEK 293 cells. Thus, the type and extent of phosphorylation, as well as the cell type in which it occurs, may be important in determining its ultimate effect on NPR activity.
In summary, we have shown that the various NPR subtypes are regulated in a negative fashion by pharmacological agonists that activate PKA and PKC in vascular cells. However, the mechanism or mechanisms underlying the inhibition, the kinetics of the effects, and the types of receptors affected are idiosyncratic to the individual signaling systems and the types of cells under examination. This type of intrinsic variability would be expected to amplify greatly the repertoire of vascular responses to the natriuretic peptides, depending on the activities of various signaling mechanisms that are operative and the relative importance of endothelial versus vascular smooth muscle cells in contributing to the ultimate biological effect being measured. Thus, the net activity of the natriuretic peptide system will be determined not only by circulating levels of the individual natriuretic peptides and the phenotypic profile of receptors available to them on the surface of target cells but also by the relative activities of the individual regulatory factors that control receptor function.
